European patent granted for amatoxin conjugates for tumor therapy

31 Mar 2020

The patent covers the crosslinking of certain carrier molecules, for example, antibodies, via specific binding sites to amatoxins.

The European Patent Office has granted Heidelberg a patent for its ADC technology for the manufacture of Antibody Amanitin Conjugates.

European patent granted for amatoxin conjugates for tumor therapy

The patent is based on a patent application and named "Amatoxin armed therapeutic cell surface binding components designed for tumor therapy". The application was submitted by Professor Heinz Faulstich and employees of the German Cancer Research Centre (DKFZ). Heidelberg Pharma exclusively in-licensed the patent in December 2009.

The subject matter of the patent is the crosslinking of certain carrier molecules, for example, antibodies, via specific binding sites to amatoxins. Amatoxins are natural poisons occurring in, for example, the death cap mushroom (Amanita phalloides). To the company's knowledge, Heidelberg Pharma is the first company worldwide to work with the corresponding toxin amanitin to develop Antibody Targeted Amanitin Conjugates (ATACs) for the use in cancer therapy.

Amanitin is known in oncology for its unique mode of action: the inhibition of RNA polymerase II, which leads the cells to programmed cell death (apoptosis) independent from cell division. This offers the opportunity to treat therapy-resistant tumors and kill quiescent tumor cells, which could result in significant clinical progress.

The chemical linkage to natural amanitin is only possible at certain positions without loss of efficacy of the molecule. The granted European patent protects the use of certain positions for the ATAC technology which are chemically easy to access, and which maintain the biologic function of the Amanitin.

Prof Andreas Pahl, Chief Scientific Officer of Heidelberg Pharma AG, commented: "We are delighted that, following the US patent, also the European patent has been granted to protect certain binding sites at our toxin amanitin. Since these binding sites at amanitin are protected independently of the structures linked to them, these patents offer strong protection of the natural substance Amanitin for use in ADC technology and protect our unique ATAC technology."

Read More

Related news

HKBU scientists develop technique to eliminate drug side effects

HKBU scientists develop technique to eliminate drug side effects

19 May 2020

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

Read more 
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

18 May 2020

CDMO is contracted to produce multiple clinical batches from German facility

Read more 
Characterizing virus and virus-like particles

Characterizing virus and virus-like particles

12 May 2020

New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

Read more 
AI technology company launches with Novartis and Sarepta deals

AI technology company launches with Novartis and Sarepta deals

11 May 2020

Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

Read more 
Bio-Rad launches anti-certolizumab pegol antibodies

Bio-Rad launches anti-certolizumab pegol antibodies

5 May 2020

Using this critical antibody reagent at the preclinical stage of development will minimize the need to revalidate assays with different reagents at the clinical development stage.

Read more 
BERG named visionary in first-ever Frost Radar AI in Drug Discovery report

BERG named visionary in first-ever Frost Radar AI in Drug Discovery report

13 Apr 2020

The biotech pioneer is one of the first companies to develop corporate partnerships in this application of artificial intelligence (AI) for drug discovery.

Read more 
AstraZeneca incredibly excited by lung cancer treatment trial

AstraZeneca "incredibly excited" by lung cancer treatment trial

13 Apr 2020

Independent Data Monitoring Committee (IDMC) recommends unblind Phase III trial of Tagrisso 2 years ahead of schedule.

Read more 
German pharma companies are meeting the corona stress test

German pharma companies are meeting the corona "stress test"

7 Apr 2020

The head of the leading German pharmaceutical industry organization says German firms are working top-speed to find coronavirus medications.

Read more 
World’s leading biobanks join a global network to advance personalized healthcare research

World’s leading biobanks join a global network to advance personalized healthcare research

6 Apr 2020

The platform enables collaboration between pharmaceutical institutions, healthcare and academic researchers to generate valuable insights and advance medical research.

Read more 
Servier strengthens its R&D pipeline with Symphogen acquisition

Servier strengthens its R&D pipeline with Symphogen acquisition

6 Apr 2020

Symphogen becomes the antibody center of excellence within Servier.

Read more